Literature DB >> 152707

Delayed cutaneous hypersensitivity in children with severe multiple handicaps treated with phenytoin.

A Higashi, I Matsuda, S Sinosuka, H Ohtsuka, F Endo, T Maeda, T Ikeda, S Miyoshino.   

Abstract

Peripheral lymphocyte counts, T-cell and B-cell populations, DNCB skin reactions, Mantoux reactions, mitogenic transformation using PHA, and determination of serum phenytoin concentration were carried out in 45 children with severe handicaps. Twenty two of these patients were receiving phenytoin treatment. When compared with control subjects, the skin reactions were significantly depressed in the handicapped children, amongst whom those treated with phenytoin had more impaired reactions than those who were untreated. No significant relationship between the results of the skin reactions and the other parameters was found.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 152707     DOI: 10.1007/bf00441358

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  14 in total

1.  Partial DiGeorge syndrome with substantial cell-mediated immunity.

Authors:  H F Pabst; W C Wright; J LeRiche; E R Stiehm
Journal:  Am J Dis Child       Date:  1976-03

2.  Human lymphocyte subpopulations. Human thymus-lymphoid tissue (HTL) antigen-positive lymphocytes forming rosettes with sheep erythrocytes and HTL antigen-negative lymphocytes interacting with antigen-antibody-complement complexes.

Authors:  J Yata; I Tsukimoto; T Tachibana
Journal:  Clin Exp Immunol       Date:  1973-07       Impact factor: 4.330

3.  Maturation of cell-surface structure of human B lymphocytes.

Authors:  J Yata; I Tsukimoto
Journal:  Lancet       Date:  1972-12-30       Impact factor: 79.321

4.  Diphenylhydantoin effects on human lymphocytes in vitro and in vivo. An hypothesis to explain some drug reactions.

Authors:  A A MacKinney; H E Booker
Journal:  Arch Intern Med       Date:  1972-06

5.  A rapid assay of cell mediated immunity to soluble antigens based on the stimulation of protein synthesis.

Authors:  S A Rosenberg; R Levy
Journal:  J Immunol       Date:  1972-04       Impact factor: 5.422

6.  Letter: Lymphocytopenia in patients treated with phenytoin.

Authors:  L Brandt; P G Nilsson
Journal:  Lancet       Date:  1976-02-07       Impact factor: 79.321

7.  Letter: Immunosuppression by phenytoin.

Authors:  M Masi; P Paolucci; P Perocco; C Franceschi
Journal:  Lancet       Date:  1976-04-17       Impact factor: 79.321

8.  Selective diphenylhydantoin-induced suppression of lymphocyte reactivity in vitro.

Authors:  A Bluming; S Homer; R Khiroya
Journal:  J Lab Clin Med       Date:  1976-09

9.  Depression of immunological function in patients treated with phenytoin sodium (sodium diphenylhydantoin).

Authors:  T C Sorrell; I J Forbes; F R Burness; R H Rischbieth
Journal:  Lancet       Date:  1971-12-04       Impact factor: 79.321

10.  Immunological abnormalities and hydantoins.

Authors:  P J Grob; G E Herold
Journal:  Br Med J       Date:  1972-06-03
View more
  4 in total

1.  Reports of two cases of autoimmune thyroiditis while receiving anticonvulsant therapy.

Authors:  S Nishiyama; M Matsukura; S Fujimoto; I Matsuda
Journal:  Eur J Pediatr       Date:  1983-04       Impact factor: 3.183

2.  Response to transfer factor to immunodeficiency in handicaps treated with phenytoin.

Authors:  T Ikeda; A Higashi; I Matsuda; S Miyoshino
Journal:  Eur J Pediatr       Date:  1979-09       Impact factor: 3.183

3.  Immunological study of IgA deficiency during anticonvulsant therapy in epileptic patients.

Authors:  H Matsuoka; J Okada; T Takahashi; M Matsuoka; C Sato; S Torii
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

4.  Association of increased numbers of peripheral blood double-negative T-lymphocytes with elevated serum IgG levels in severely handicapped children.

Authors:  Y Kawano; T Noma; I Yoshizawa; K Maruki; J Yata
Journal:  Eur J Pediatr       Date:  1994-12       Impact factor: 3.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.